For instance, hyperactivation of mTORC1 in AML is driven by mutated oncogenic upstream drivers (e.g., RAS, FLT3) and by the in vivo AML microenvironment, contributing to disease progression and relapse [18–26]. The gene discussed is FLT3; the disease is acute myeloid leukemia.